Nuclear Medicine/Radiopharmaceuticals Global Market - Forecast To 2027

Publishing Date : September, 2020
Report Code : HCPH 0099
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Over the past 50 years, the nuclear medicine field has displayed a strong link between investments in chemistry and the development of radionuclide and radio-labeled compounds which have impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular levels for probing, tracking tissue function, study disease progression and assessing treatment responses.

The nuclear medicine global market is poised to grow at a high single digit CAGR from 2020 to 2027 to reach $10,742.7 million by 2027. Increasing radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear medicine market.

The nuclear medicinal market is classified based on modality into diagnosis and therapeutics. The diagnostics market commanded the largest market revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 due to an increase in SPECT and PET procedures. The therapeutics segment is projected to grow at high teen CAGR from 2020 to 2027 due to technological advancements in the targeted treatment of cancers. Potential new radioisotopes in the pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnosis by products is segmented into SPECT and PET. SPECT market commanded the largest revenue in 2020 and is expected to grow at low single digit CAGR from 2020 to 2027 due to an increase in TC-99m isotope applications and product approvals. Among SPECT is segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Samarium (Sm-153), Xenon (Xe-133), Rhenium (Re-186) and others. Technetium (Tc-99m) accounted for the largest share in 2020 and is projected to grow at a mid single digit CAGR from 2020 to 2027 due to its extensive usage in various diagnostic applications and emerging sources to meet the demand. SPECT market by application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. Cardiology accounted for the largest share in 2020 and is expected to grow at mid single digit CAGR from 2020 to 2027 due to an increase in the number of cardiac imaging cases using Tc-99m. Oncology is expected to grow at mid single digit CAGR from 2020 to 2027 due to increasing expanding usage in early screening tests in vulnerable populations in various developed countries.

PET is the fastest-growing segment with mid single digit CAGR from 2020 to 2027 due to an increase in the adoption of cyclotron for the production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027. Gallium (Ga-68) is expected to grow at high double digit CAGR from 2020 to 2027 due to an increase in usage as theranostic pair in assessing the suitability of patient for Lutathera and many emerging targeted radiotherapy agents. PET by applications is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for the largest share in 2020 and is projected to grow at high single digit CAGR from 2020 to 2027 due to an increase in the patient pool of lung, thyroid, brain breast cancer and dementia related conditions.

The therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy. Beta radiation accounted for the largest share of in 2020 and is projected to grow at high double digit CAGR of from 2020 to 2027. Beta radiation therapy by isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. Lu-177 commanded the largest share in 2020 and is expected to grow at high double digit CAGR from 2020 to 2027 due to increased adoption of Lu-177 based radiopharmaceuticals for the treatment of neuroendocrine tumor and anticipated launch of new treatment products based on the isotope. Strontium (Sr-89) is expected to grow at a strong CAGR from 2020 to 2027. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others. I-125 market accounted for the largest share in 2020 and is projected to grow at low single digit CAGR from 2020 to 2027 due to increasing usage in the treatment of lung cancer, prostate cancer, eye-related disease (retinoblastoma and eye plaque) and brain cancer. Therapeutic nuclear medicine by application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors (GEP-NETs), metastatic bone cancer, breast cancer and others. The GEP-NETs market accounted for the largest share in 2020 and is expected to grow at high double digit CAGR from 2020 to 2027. Prostate Cancer is expected to grow at a strong CAGR from 2020 to 2027 due to advanced clinical trial stage (phase 3) and predicted launch of Lu-177 PSMA-617 product in 2021.

Nuclear medicine based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers and others. Hospital accounted for the largest share in 2020 and is projected to grow at high double digit CAGR from 2020 to 2027 due to the ready availability of cyclotrons for the generation of isotope and use of advanced hybrid imaging.

The stable isotope global market is expected to grow at low single digit CAGR from 2020 to 2027 to reach $284.3 million by 2027. The Nuclear Medicine market includes stable isotopes are classified into isotopes and applications. Isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), Sulphur (S-32) and others. Deuterium (D-2) accounted the largest share n 2020 and is the fastest-growing market with a projected CAGR of 3.3% from 2020 to 2027 due to the use of deuterium as a dietary supplement of deuterium-depleted water which helps to extend the survival rate of lung cancer patient via exerting anticancer effect and modification of deuterium leads to the development of novel, highly differentiated drugs which have therapeutic applications in diabetic nephropathy, hot flashes, spasticity, neuropathic pain and multiple melanomas. The stable isotope applications market is segmented into diagnostics-therapy, pharmaceutical companies and others. The diagnostics and therapy market commanded the largest market revenue in 2020 and is expected grow at low single digit CAGR from 2020 to 2027 due to use in diagnosis and treatment of pancreas, liver and intestine related disorders. The pharmaceuticals is the fastest-growing segment at low single digit CAGR from 2020 to 2027 due to novel developments in the utilization of stable isotopes that involve biopolymers, where isotope-labeled species are generated from cells grown on labeled growth media.

Geographical wise, North American region commanded the largest revenue in 2020 and is expected to grow at low single digit CAGR from 2020 to 2027. The growing use of SPECT and PET scans, technological advancements in equipment, increased utilization of fusion imaging, increasing awareness of radiopharmaceuticals among radiologists, alpha radio-immunotherapy-based targeted cancer treatment are driving the market.

Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer Group (Germany), GE Healthcare (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), and Fujifilm Holding Corporation (Japan).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAY
    • 2.2     REPORT SCOPE
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING APPLICATIONS OF RADIOPHARMACEUTICALS
        • 3.3.1.2     PRODUCTION OF RADIOPHARMACEUTICALS FROM CYCLOTRONS
        • 3.3.1.3     EFFICIENT DIAGNOSIS AND TREATMENTS
        • 3.3.1.4     INCREASING INTEREST IN THERANOSTICS
        • 3.3.1.5     RISE IN PUBLIC AWARENESS
        • 3.3.1.6     TECHNOLOGICAL ADVANCEMENTS
        • 3.3.1.7     INCREASING DEMAND IN EMERGING MARKETS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     THE SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS
        • 3.3.2.2     HIGH COST AND SUPPLY SHORTAGE OF ISOTOPES
        • 3.3.2.3     RADIO TOXICITY
        • 3.3.2.4     SHORTAGE OF QUALIFIED TECHNICIANS
        • 3.3.2.5     WITHDRAWAL OF RADIOPHARMACY PRODUCTS DUE TO LIMITED COMMERCIAL ADOPTION
        • 3.3.2.6     REGULATORY ISSUES
        • 3.3.2.7     THREAT FROM TRADITIONAL/ALTERNATIVE DIAGNOSTIC PROCEDURES
        • 3.3.2.8     HUGE CAPITAL INVESTMENT
    • 3.4     PROBLEM AREAS
      • 3.4.1     CLOSURE OF REACTORS
    • 3.5     WINNING IMPERATIVES
      • 3.5.1     AVAILABILITY OF TECHNETIUM
    • 3.6     REGULATORY GUIDELINES
      • 3.6.1     UNITED STATES
      • 3.6.2     EUROPE
      • 3.6.3     JAPAN
      • 3.6.4     INDIA
      • 3.6.5     CHINA
      • 3.6.6     SOUTH KOREA
    • 3.7     REIMBURSEMENT SCENARIO AND CHALLENGES
    • 3.8     CLINICAL TRIALS
    • 3.9     EMERGING ISOTOPES
    • 3.10     TECHNOLOGICAL ADVANCEMENTS
      • 3.10.1     COMPTON CAMERA
      • 3.10.2     SUBTLE PET
      • 3.10.3     PRODUCTION OF ISOTOPES THROGUH CYCLOTRONS
      • 3.10.4     LINAC BASED TC-99M PRODUCTION
      • 3.10.5     AUGER ELECTRONS
    • 3.11     SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE
      • 3.11.1     REACTORS
      • 3.11.2     CYCLOTRON
      • 3.11.3     GENERATORS
      • 3.11.4     LINAC BASED TC-99M PRODUCTION METHOD
      • 3.11.5     PROCESSING FACILITY
      • 3.11.6     HOSPITALS AND CENTRAL RADIO PHARMACIES
    • 3.12     LIST OF POTENTIAL NEW REACTORS
    • 3.13     LIST OF FDA APPROVED RADIOPHARMACEUTICALS
    • 3.14     PORTER'S FIVE FORCE ANALYSIS
      • 3.14.1     THREAT OF NEW ENTRANTS
      • 3.14.2     THREAT OF SUBSTITUTES
      • 3.14.3     COMPETITIVE RIVALRY
      • 3.14.4     BARGAINING POWER OF SUPPLIERS
      • 3.14.5     BARGAINING POWER OF BUYERS
    • 3.15     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.15.1     NUCLEAR MEDICINE MARKET
      • 3.15.2     SPECT MARKET
      • 3.15.3     PET MARKET
      • 3.15.4     NUCLEAR MEDICINE THERAPEUTIC MARKET
      • 3.15.5     TC-99 MARKET
      • 3.15.6     F-18 MARKET
      • 3.15.7     GA-68 MARKET
      • 3.15.8     RB-82 MARKET
    • 3.16     NUCLEAR MEDICINE-FUNDING SCENARIO
    • 3.17     NUCLEAR MEDICINE – DEALS AND APPROVALS
  • 4     NUCLEAR MEDICINE GLOBAL MARKET, BY MODALITY
    • 4.1     INTRODUCTION
    • 4.2     DIAGNOSTICS
      • 4.2.1     NUCLEAR MEDICINE FOR DIAGNOSIS, BY ISOTOPES
        • 4.2.1.1     SPECT, BY ISOTOPES
          • 4.2.1.1.1     TECHNETIUM (TC-99M)
          • 4.2.1.1.2     THALLIUM (TL-201)
          • 4.2.1.1.3     GALLIUM (GA-67)
          • 4.2.1.1.4     IODINE (I-123)
          • 4.2.1.1.5     SAMARIUM (SM-153)
          • 4.2.1.1.6     XENON (XE-133)
          • 4.2.1.1.7     RHENIUM (RE-186)
          • 4.2.1.1.8     OTHERS (IN-111, Y-90, CR-51)
        • 4.2.1.2     PET, BY ISOTOPES
          • 4.2.1.2.1     FLUORODEOXYGLUCOSE (18F-FDG)
          • 4.2.1.2.2     GALLIUM (GA-68)
            • 4.2.1.2.2.1     PRODUCTION ANALYSIS OF GALLIUM-68 (GA-68)
          • 4.2.1.2.3     RUBIDIUM (RB-82)
            • 4.2.1.2.3.1     PRODUCTION ANALYSIS OF STRONTIUM (SR-82)/ RUBIDIUM (RB-82)
          • 4.2.1.2.4     OTHERS (C-11, N-13, CU-64, ZR-89)
      • 4.2.2     NUCLEAR MEDICINE FOR DIAGNOSIS, BY APPLICATION
        • 4.2.2.1     SPECT BY APPLICATION
          • 4.2.2.1.1     CARDIOLOGY
          • 4.2.2.1.2     PULMONARY
          • 4.2.2.1.3     ONCOLOGY
          • 4.2.2.1.4     NEPHROLOGY
          • 4.2.2.1.5     NEUROLOGY
          • 4.2.2.1.6     INFLAMMATION
          • 4.2.2.1.7     THYROID GLANDS
          • 4.2.2.1.8     LYMPHOLOGY
          • 4.2.2.1.9     OTHERS
        • 4.2.2.2     PET BY APPLICATION
          • 4.2.2.2.1     ONCOLOGY
          • 4.2.2.2.2     NEUROLOGY
          • 4.2.2.2.3     CARDIOLOGY
          • 4.2.2.2.4     INFLAMMATION
          • 4.2.2.2.5     OTHERS
    • 4.3     THERAPEUTICS
      • 4.3.1     NUCLEAR MEDICINE FOR THERAPEUTICS, BY RADIATION TYPE
        • 4.3.1.1     BETA RADIATION THERAPY
          • 4.3.1.1.1     YTTRIUM (Y-90)
          • 4.3.1.1.2     IODINE (I-131)
          • 4.3.1.1.3     LUTETIUM (LU-177)
            • 4.3.1.1.3.1     DEMAND AND PRODUCTION ANALYSIS OF LUTITIUM-177 (LU-177)
          • 4.3.1.1.4     SAMARIUM (SM-153)
          • 4.3.1.1.5     RHENIUM (RE-186)
          • 4.3.1.1.6     STRONTIUM (SR-89)
          • 4.3.1.1.7     ERBIUM (ER-169)
          • 4.3.1.1.8     OTHERS
        • 4.3.1.2     ALPHA RADIATION THERAPY
          • 4.3.1.2.1     RADIUM (RA-223)
            • 4.3.1.2.1.1     ANALYSIS OF RADIUM-223 (RA-223)
          • 4.3.1.2.2     EMERGING ALPHA RADIATION ISOTOPES
            • 4.3.1.2.2.1     PRODUCTION ANALYSIS OF ACTINIUM-225 (AC-225) AND BISMUTH-213 (BI-213)
        • 4.3.1.3     BRACHYTHERAPY, BY ISOTOPES
          • 4.3.1.3.1     IODINE (I-125)
          • 4.3.1.3.2     CESIUM (CS-131)
          • 4.3.1.3.3     IRIDIUM (IR-192)
          • 4.3.1.3.4     PALLADIUM (PD-103)
          • 4.3.1.3.5     OTHERS
        • 4.3.1.4     NUCLEAR MEDICINE THERAPEUTICS, BY APPLICATION
        • 4.3.1.5     PROSTATE CANCER
        • 4.3.1.6     THYROID CANCER
        • 4.3.1.7     LIVER CANCER
        • 4.3.1.8     GEP-NET THERAPEUTICS
        • 4.3.1.9     METASTATIC BONE CANCER THERAPEUTICS
        • 4.3.1.10     BREAST CANCER THERAPEUTICS
        • 4.3.1.11     OTHER APPLICATIONS
  • 5     NUCLEAR MEDICINE GLOBAL MARKET, BY END-USERS
    • 5.1     INTRODUCTION
    • 5.2     HOSPITAL
    • 5.3     AMBULATORY CENTERS
    • 5.4     DIAGNOSTIC CENTERS
    • 5.5     OTHER END-USERS
  • 6     STABLE ISOTOPES
    • 6.1     INTRODUCTION
    • 6.2     MARKET ANALYSIS
      • 6.2.1     FACTORS INFLUENCING MARKET
      • 6.2.2     DRIVERS AND OPPORTUNITIES
        • 6.2.2.1     INCREASE IN RESEARCH ACTIVITIES (PHARMACEUTICALS AND BIOTECHNOLOGY SECTORS)
        • 6.2.2.2     INCREASING APPLICATIONS
      • 6.2.3     RESTRAINTS AND THREATS
        • 6.2.3.1     HIGH COST OF STABLE ISOTOPES
        • 6.2.3.2     STABLE ISOTOPES-SIDE EFFECTS AND SAFETY ISSUES
        • 6.2.3.3     STRINGENT REGULATIONS FOR MANUFACTURING AND USE OF STABLE ISOTOPES
    • 6.3     STABLE ISOTOPES MARKET, BY ISOTOPE
      • 6.3.1     CARBON (C-13)
      • 6.3.2     DEUTERIUM (D2)
      • 6.3.3     OXYGEN (O-18)
      • 6.3.4     NITROGEN (N-15)
      • 6.3.5     SULPHUR (S-32)
      • 6.3.6     OTHERS
    • 6.4     STABLE ISOTOPES MARKET, BY APPLICATION
      • 6.4.1     INTRODUCTION
      • 6.4.2     DIAGNOSTICS AND THERAPY
      • 6.4.3     PHARMACEUTICALS
      • 6.4.4     OTHERS
    • 6.5     STABLE ISOTOPES MARKET, BY GEOGRAPHY
      • 6.5.1     INTRODUCTION
      • 6.5.2     NORTH AMERICA
      • 6.5.3     EUROPE
      • 6.5.4     ASIA-PACIFIC
      • 6.5.5     REST OF THE WORLD
  • 7     NUCLEAR MEDICINE GLOBAL MARKET BY REGION
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF N.A.
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     ITALY
      • 7.3.4     REST OF E.U.
    • 7.4     APAC
      • 7.4.1     JAPAN
      • 7.4.2     CHINA
      • 7.4.3     SOUTH KOREA
      • 7.4.4     REST OF APAC
    • 7.5     REST OF THE WORLD
      • 7.5.1     TURKEY
      • 7.5.2     BRAZIL
      • 7.5.3     OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     APPROVALS
    • 8.3     COLLABORATION
    • 8.4     ACQUISITION
    • 8.5     EXPANSION
    • 8.6     OTHERS
  • 9     MAJOR PLAYER PROFILES
    • 9.1     BAYER GROUP
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     BRACCO S.P.A
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     CARDINAL HEALTH INC.
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.)
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     CURIUM PHARMA
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     FUJIFILM HOLDINGS CORPORATION
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     GE HEALTHCARE
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     JUBILANT LIFE SCIENCES
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     LANTHEUS MEDICAL IMAGING, INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     NOVARTIS INTERNATIONAL AG
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 2     REIMBURSEMENT RATES FOR RADIOPHARMACEUTICALS AND DIAGNOSTIC IMAGING TECHNIQUES
      • TABLE 3     NUCLEAR MEDICINE CLINICAL TRIALS
      • TABLE 4     NUCLEAR MEDICINE EMERGING ISOTOPES
      • TABLE 5     TECHNETIUM (TC-99M) REACTORS
      • TABLE 6     NEW POTENTIAL REACTORS
      • TABLE 7     FDA APPROVED RADIOPHARMACEUTICALS
      • TABLE 8     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY MODALITY, (2019-2027) ($MN)
      • TABLE 9     NUCLEAR MEDICINE DIAGNOSTIC, THERAPEUTIC AND OVERALL PROCEDURAL VOLUME (2020) (NOS.)
      • TABLE 10     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
      • TABLE 11     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 12     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 13     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 14     TECHNETIUM (TC-99M) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 15     THALLIUM (TL-201) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 16     GALLIUM (GA-67) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 17     IODINE (I-123) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 18     SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 19     XENON (XE-133) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 20     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 21     OTHER SPECT ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 22     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY ISOTOPES, (2019-2027) ($MN)
      • TABLE 23     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 24     FLUORODEOXYGLUCOSE (18F-FDG) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 25     GALLIUM (GA-68) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 26     GALLIUM (GA-68) GENERATOR SUPPLIERS
      • TABLE 27     GA (GA-68) NUMBER OF DOSES SOLD DURING 2020
      • TABLE 28     RUBIDIUM (RB-82) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 29     STRONTIUM (SR-82)/RUBIDIUM (RB-82) GENERATOR SUPPLIERS
      • TABLE 30     OTHER PET ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 31     NUCLEAR MEDICINE SPECT GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 32     CARDIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 33     PULMONARY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 34     ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 35     NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 36     NEUROLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 37     INFLAMMATION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 38     THYROID GLANDS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 39     LYMPHOLOGY SPECT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 40     OTHER SPECT APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 41     NUCLEAR MEDICINE PET GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 42     ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 43     NEUROLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 44     CARDIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 45     INFLAMMATION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 46     OTHERS PET APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 47     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY RADIATION TYPE, (2019-2027) ($MN)
      • TABLE 48     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 49     BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY ISOTOPES, (2019-2027) ($MN)
      • TABLE 50     BETA RADIATION THERAPY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 51     YTTRIUM (Y-90) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 52     IODINE(I-131) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 53     LUTETIUM (LU-177) SUPPLIERS AND PRODUCTION CAPACITY
      • TABLE 54     LUTETIUM (LU-177) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 55     LUTETIUM (LU-177) NUMBER OF DOSES SOLD AND PATIENTS TREATED DURING 2020
      • TABLE 56     SAMARIUM (SM-153) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 57     RHENIUM (RE-186) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 58     STRONTIUM (SR-89) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 59     ERBIUM (ER-169) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 60     OTHER BETA RADIATION THERAPY ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 61     ALPHA RADIATION THERAPY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 62     ACTINIUM (AC-225) CURRENT AND FUTURE SUPPLIERS
      • TABLE 63     BRACHYTHERAPY GLOBAL MARKET REVENUE, BY ISOTOPES, (2019-2027) ($MN)
      • TABLE 64     BRACHYTHERAPY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 65     IODINE (I-125) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 66     CESIUM (CS-131) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 67     IRIDIUM (IR-192) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 68     PALLADIUM (PD-103) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 69     OTHER BRACHYTHERAPY ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 70     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 71     PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 72     THYROID CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 73     LIVER CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 74     GEP-NET GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 75     METASTATIC BONE CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 76     BREAST CANCER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 77     OTHER THERAPEUTIC APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 78     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 79     HOSPITAL GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 80     AMBULATORY CENTERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 81     DIAGNOSTIC CENTERS END-USER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 82     OTHER END-USER GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 83     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 84     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 85     CARBON (C-13) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 86     DEUTERIUM (D2) GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 87     OXYGEN (O-18) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 88     NITROGEN (N-15) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 89     SULPHUR (S-32) ISOTOPE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 90     OTHER STABLE ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 91     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 92     DIAGNOSTICS-THERAPY APPLICATION GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 93     PHARMACEUTICALS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 94     OTHERS GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 95     STABLE ISOTOPES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 96     NORTH AMERICA STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 97     NORTH AMERICA STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2020-2027) ($MN)
      • TABLE 98     EUROPE STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 99     EUROPE STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 100     ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 101     ASIA-PACIFIC STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 102     REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 103     REST OF THE WORLD STABLE ISOTOPES MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 104     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
      • TABLE 105     NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2019-2027) ($MN)
      • TABLE 106     NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
      • TABLE 107     NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 108     NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 109     NORTH AMERICA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 110     NORTH AMERICA NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 111     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2019-2027) ($MN)
      • TABLE 112     NORTH AMERICA NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 113     NORTH AMERICA NUCLEAR MEDICINE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 114     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 115     NORTH AMERICA NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 116     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2019-2027) ($MN)
      • TABLE 117     EUROPE NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
      • TABLE 118     EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 119     EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 120     EUROPE NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 121     EUROPE NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 122     EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2019-2027) ($MN)
      • TABLE 123     EUROPE NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 124     EUROPE BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 125     EUROPE NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 126     EUROPE NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 127     APAC NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2019-2027) ($MN)
      • TABLE 128     APAC NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
      • TABLE 129     APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 130     APAC NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 131     APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 132     APAC NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 133     APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2019-2027) ($MN)
      • TABLE 134     APAC NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 135     APAC BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 136     APAC NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 137     APAC NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 138     ROW NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2019-2027) ($MN)
      • TABLE 139     ROW NUCLEAR MEDICINE DIAGNOSTICS MARKET REVENUE, BY PRODUCTS, (2019-2027) ($MN)
      • TABLE 140     ROW NUCLEAR MEDICINE SPECT MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 141     ROW NUCLEAR MEDICINE PET MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 142     ROW NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 143     ROW NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 144     ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY RADIATION TYPE, (2019-2027) ($MN)
      • TABLE 145     ROW NUCLEAR MEDICINE BETA RADIATION THERAPY MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 146     ROW BRACHYTHERAPY MARKET REVENUE, BY ISOTOPE, (2019-2027) ($MN)
      • TABLE 147     ROW NUCLEAR MEDICINE THERAPEUTICS MARKET REVENUE, BY APPLICATION, (2019-2027) ($MN)
      • TABLE 148     ROW NUCLEAR MEDICINE MARKET REVENUE, BY END-USERS, (2019-2027) ($MN)
      • TABLE 149     APPROVALS (2019-2020)
      • TABLE 150     COLLABORATION (2019-2020)
      • TABLE 151     ACQUISITION (2018-2020)
      • TABLE 152     EXPANSIONS (2019-2020)
      • TABLE 153     OTHERS (2019-2020)
      • TABLE 154     BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2) ($MN)
      • TABLE 155     BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2018-2020) (Q2) ($MN)
      • TABLE 156     BAYER GROUP: PHARMACEUTICAL SEGMENT TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) (Q2) ($MN)
      • TABLE 157     CARDINAL HEALTH, INC.: TOTAL REVENUE AND R&D EXPENSES (2018-2020) (Q3) ($MN)
      • TABLE 158     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENTS, (2018 -2020) (Q3) ($MN)
      • TABLE 159     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) (Q3) ($MN)
      • TABLE 160     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017 – 2019) ($MN)
      • TABLE 161     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
      • TABLE 162     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2017 – 2019) ($MN)
      • TABLE 163     GE HEALTHCARE: TOTAL REVENUE AND R&D EXPENSES (2018 – 2020) (Q2) ($MN)
      • TABLE 164     GE HEALTHCARE: TOTAL REVENUE, BY SEGMENTS (2018-2020) (Q2) ($MN)
      • TABLE 165     GE HEALTHCARE: TOTAL REVENUE, BY GEOGRAPHY (2018 –2020) (Q2) ($MN)
      • TABLE 166     JUBILANT LIFE SCIENCES: TOTAL REVENUE AND R&D EXPENSES (2017 – 2019) ($MN)
      • TABLE 167     JUBILANT LIFE SCIENCES: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
      • TABLE 168     JUBILANT LIFE SCIENCES: PHARMACEUTICAL TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
      • TABLE 169     JUBILANT LIFE SCIENCES: SPCEIALTY PHARMACEUTICAL TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
      • TABLE 170     JUBILANT LIFE SCIENCES: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($BN)
      • TABLE 171     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) (Q2) ($MN)
      • TABLE 172     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2018-2020) (Q2) ($MN)
      • TABLE 173     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) (Q2) ($MN)
      • TABLE 174     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE AND R&D EXPENSES (2018-2020) (Q2) ($MN)
      • TABLE 175     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY SEGMENTS (2018-2020) (Q2) ($MN)
      • TABLE 176     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY INNOVATIVE MEDICINE SEGMENT (2018-2020) (Q2) ($MN)
      • TABLE 177     NOVARTIS INTERNATIONAL AG: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     NUCLEAR MEDICINE GLOBAL MARKET SHARE AND REVENUE, BY REGION, (2019-2027) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: NUCLEAR MEDICINE GLOBAL MARKET
      • FIGURE 3     NUCLEAR MEDICINE GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     NUCLEAR MEDICINE GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     NUCLEAR MEDICINE GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     DIAGNOSTICS NUCLEAR GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 8     THERAPEUTIC NUCLEAR MEDICINE GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 9     STABLE ISOTOPES GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 10     MARKET DYNAMICS
      • FIGURE 11     TECHNETIUM -99: SUPPLY CHAIN ANALYSIS
      • FIGURE 12     NUCLEAR MEDICINE MARKET: PORTER’S ANALYSIS
      • FIGURE 13     NUCLEAR MEDICINE GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
      • FIGURE 14     SPECT ISOTOPES: MAJOR PLAYER MARKET SHARE ANALYSIS (2020) (%)
      • FIGURE 15     PET ISOTOPES: MAJOR PLAYERS MARKET SHARE ANALYSIS (2020) (%)
      • FIGURE 16     NUCLEAR MEDICINE THERAPEUTIC: MAJOR PLAYERS MARKET SHARE ANALYSIS (2020) (%)
      • FIGURE 17     TC -99M: MAJOR PLAYERS MARKET SHARE ANALYSIS (2020) (%)
      • FIGURE 18     F-18: MAJOR PLAYERS MARKET SHARE ANALYSIS (2020) (%)
      • FIGURE 19     GA-68: MAJOR PLAYERS MARKET SHARE ANALYSIS (2020) (%)
      • FIGURE 20     RB-82: MAJOR PLAYERS MARKET SHARE ANALYSIS (2020) (%)
      • FIGURE 21     NUCLEAR MEDICINE GLOBAL MARKET SHARE, BY MODALITY, (2020 V/S 2027) (%)
      • FIGURE 22     NUCLEAR MEDICINE ISOTOPES, BY MODALITY
      • FIGURE 23     SPECT GLOBAL PROCEDURAL VOLUME BY REGION AND BY COUNTRY (NOS.)
      • FIGURE 24     TC-99M GLOBAL PROCEDURAL VOLUME BY REGION AND BY COUNTRY (NOS.)
      • FIGURE 25     PET GLOBAL PROCEDURAL VOLUME BY REGION (NOS.)
      • FIGURE 26     NUCLEAR MEDICINE DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCTS, (2020 V/S 2027) (%)
      • FIGURE 27     NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 28     NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 29     NUCLEAR MEDICINE SPECT GLOBAL MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 30     NUCLEAR MEDICINE SPECT ISOTOPES, BY APPLICATION
      • FIGURE 31     NUCLEAR MEDICINE PET GLOBAL MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 32     NUCLEAR MEDICINE PET ISOTOPES, BY APPLICATION
      • FIGURE 33     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BY RADIATION TYPE, (2020 V/S 2027) (%)
      • FIGURE 34     BETA RADIATION THERAPY GLOBAL MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 35     LU-177 BASED THERAPY (LUTATHERA), GLOBAL MARKET PENETRATION, (2020) (%)
      • FIGURE 36     LU-177 BASED THERAPY (LUTATHERA), NORTH AMERICA MARKET PENETRATION, (2020) (%)
      • FIGURE 37     LU-177 BASED THERAPY (LUTATHERA), EUROPE MARKET PENETRATION, (2020) (%)
      • FIGURE 38     LU-177 BASED THERAPY (LUTATHERA), ASIA-PACIFIC MARKET PENETRATION, (2020) (%)
      • FIGURE 39     LU-177 BASED THERAPY (LUTATHERA), ROW MARKET PENETRATION, (2020) (%)
      • FIGURE 40     NUCLEAR MEDICINE BRACHYTHERAPY GLOBAL MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 41     NUCLEAR MEDICINE THERAPEUTICS GLOBAL MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 42     NUCLEAR MEDICINE THERAPEUTIC ISOTOPES, BY APPLICATION
      • FIGURE 43     NUCLEAR MEDICINE GLOBAL MARKET SHARE, BY END-USERS, (2020 V/S 2027) (%)
      • FIGURE 44     STABLE ISOTOPES MARKET: MARKET DYNAMICS
      • FIGURE 45     STABLE ISOTOPES GLOBAL MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 46     STABLE ISOTOPES GLOBAL MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 47     STABLE ISOTOPE GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
      • FIGURE 48     NORTH AMERICA STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 49     NORTH AMERICA STABLE ISOTOPES MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 50     EUROPE STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 51     EUROPE STABLE ISOTOPES MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 52     ASIA-PACIFIC STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 53     ASIA-PACIFIC STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 54     REST OF THE WORLD STABLE ISOTOPES MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 55     REST OF THE WORLD STABLE ISOTOPES MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 56     NUCLEAR MEDICINE GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
      • FIGURE 57     NUCLEAR MEDICINE GLOBAL MARKET SHARE BY REGION AND MARKET REVENUE BY COUNTRY, (2020) (%) ($MN)
      • FIGURE 58     NORTH AMERICA NUCLEAR MEDICINE MARKET SHARE, BY MODALITY (2020 V/S 2027) (%)
      • FIGURE 59     NORTH AMERICA NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2020 V/S 2027) (%)
      • FIGURE 60     NORTH AMERICA SPECT MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 61     NORTH AMERICA PET MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 62     NORTH AMERICA SPECT MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 63     NORTH AMERICA PET MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 64     NORTH AMERICA THERAPEUTIC MARKET SHARE, BY RADIATION TYPE, (2020 V/S 2027) (%)
      • FIGURE 65     NORTH AMERICA BETA RADIATION THERAPY MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 66     NORTH AMERICA BRACHYTHERAPY MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 67     NORTH AMERICA NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 68     NORTH AMERICA NUCLEAR MEDICINE SHARE, BY END-USER, (2020 V/S 2027) (%)
      • FIGURE 69     NORTH AMERICA NUCLEAR MEDICINE SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 70     U.S. NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 71     U.S. DIAGNOSTIC NUCLEAR MEDICINE MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 72     U.S. NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 73     U.S. PET NUCLEAR MEDICINE MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 74     U.S. NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 75     U.S. NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 76     REST OF N.A. NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 77     REST OF N.A. DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 78     REST OF N.A. NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 79     REST OF N.A. NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 80     REST OF N.A. NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 81     REST OF N.A. NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 82     EUROPE NUCLEAR MEDICINE MARKET SHARE, BY MODALITY (2020 V/S 2027) (%)
      • FIGURE 83     EUROPE NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2020 V/S 2027) (%)
      • FIGURE 84     EUROPE SPECT MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 85     EUROPE PET MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 86     EUROPE SPECT MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 87     EUROPE PET MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 88     EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY RADIATION TYPE, (2020 V/S 2027) (%)
      • FIGURE 89     EUROPE BETA RADIATION THERAPY MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 90     EUROPE BRACHYTHERAPY MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 91     EUROPE NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 92     EUROPE NUCLEAR MEDICINE SHARE, BY END-USER, (2020 V/S 2027) (%)
      • FIGURE 93     EUROPE NUCLEAR MEDICINE SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 94     GERMANY NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 95     GERMANY NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 96     GERMANY NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 97     GERMANY NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 98     GERMANY NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 99     GERMANY NUCLEAR MEDICINE MARKET REVENUE BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 100     FRANCE NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 101     FRANCE NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 102     FRANCE NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 103     FRANCE NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 104     FRANCE NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 105     FRANCE NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 106     ITALY NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 107     ITALY NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 108     ITALY NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 109     ITALY NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 110     ITALY NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 111     ITALY NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 112     REST OF E.U. NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 113     REST OF E.U. NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 114     REST OF E.U. NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 115     REST OF E.U. NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 116     REST OF E.U. NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 117     REST OF E.U. NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 118     APAC NUCLEAR MEDICINE MARKET SHARE, BY MODALITY (2020 V/S 2027) (%)
      • FIGURE 119     APAC NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2020 V/S 2027) (%)
      • FIGURE 120     APAC NUCLEAR MEDICINE SPECT MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 121     APAC NUCLEAR MEDICINE PET MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 122     APAC NUCLEAR MEDICINE SPECT MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 123     APAC NUCLEAR MEDICINE PET MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 124     APAC NUCLEAR MEDICINE THERAPEUTICS MARKET SHARE, BY RADIATION TYPE, (2020 V/S 2027) (%)
      • FIGURE 125     APAC BETA RADIATION THERAPY MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 126     APAC BRACHYTHERAPY MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 127     APAC NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 128     APAC NUCLEAR MEDICINE MARKET SHARE, BY END-USER, (2020 V/S 2027) (%)
      • FIGURE 129     APAC NUCLEAR MEDICINE MARKET SHARE, BY COUNTRY, (2020 V/S 2027) (%)
      • FIGURE 130     JAPAN NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 131     JAPAN NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 132     JAPAN NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 133     JAPAN NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION,(2020 V/S 2027) ($MN)
      • FIGURE 134     JAPAN NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE BY APPLICATION (2020) ($MN)
      • FIGURE 135     JAPAN NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 136     CHINA NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 137     CHINA NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 138     CHINA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 139     CHINA NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 140     CHINA NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 141     CHINA NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 142     SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 143     SOUTH KOREA NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT,(2020 V/S 2027) ($MN)
      • FIGURE 144     SOUTH KOREA NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 145     SOUTH KOREA NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 146     SOUTH KOREA NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 147     SOUTH KOREA NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 148     REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 149     REST OF APAC NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 150     REST OF APAC NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 151     REST OF APAC NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 152     REST OF APAC NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020) ($MN)
      • FIGURE 153     REST OF APAC NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 154     ROW NUCLEAR MEDICINE MARKET SHARE, BY MODALITY (2020 V/S 2027) (%)
      • FIGURE 155     ROW NUCLEAR MEDICINE DIAGNOSTIC MARKET SHARE, BY PRODUCT, (2020 V/S 2027) (%)
      • FIGURE 156     ROW NUCLEAR MEDICINE SPECT MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 157     ROW NUCLEAR MEDICINE PET MARKET SHARE, BY ISOTOPES, (2020 V/S 2027) (%)
      • FIGURE 158     ROW NUCLEAR MEDICINE SPECT MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 159     ROW NUCLEAR MEDICINE PET MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 160     ROW NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY RADIATION TYPE, (2020 V/S 2027) (%)
      • FIGURE 161     ROW BETA RADIATION THERAPY MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 162     ROW BRACHYTHERAPY MARKET SHARE, BY ISOTOPE, (2020 V/S 2027) (%)
      • FIGURE 163     ROW NUCLEAR MEDICINE THERAPEUTIC MARKET SHARE, BY APPLICATION, (2020 V/S 2027) (%)
      • FIGURE 164     ROW NUCLEAR MEDICINE SHARE, BY END-USER, (2020 VS 2027) (%)
      • FIGURE 165     ROW NUCLEAR MEDICINE MARKET SHARE, BY COUNTRY, (2020 VS 2027) (%)
      • FIGURE 166     TURKEY NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 167     TURKEY NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 168     TURKEY NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 169     TURKEY NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 170     TURKEY NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 171     TURKEY NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 172     BRAZIL NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 173     BRAZIL NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 174     BRAZIL NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 175     BRAZIL NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 176     BRAZIL NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 177     BRAZIL NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 178     OTHER NUCLEAR MEDICINE MARKET REVENUE, BY MODALITY, (2020 V/S 2027) ($MN)
      • FIGURE 179     OTHERS NUCLEAR MEDICINE DIAGNOSTIC MARKET REVENUE, BY PRODUCT, (2020 V/S 2027) ($MN)
      • FIGURE 180     OTHERS NUCLEAR MEDICINE SPECT MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 181     OTHERS NUCLEAR MEDICINE PET MARKET REVENUE, BY APPLICATION, (2020 V/S 2027) ($MN)
      • FIGURE 182     OTHERS NUCLEAR MEDICINE THERAPEUTIC MARKET REVENUE, BY APPLICATION (2020 V/S 2027) ($MN)
      • FIGURE 183     OTHERS NUCLEAR MEDICINE MARKET REVENUE, BY END-USER, (2020 V/S 2027) ($MN)
      • FIGURE 184     KEY GROWTH STRATEGIES (2019-2020)
      • FIGURE 185     SWOT: BAYER GROUP
      • FIGURE 186     SWOT: BRACCO S.P.A
      • FIGURE 187     SWOT: CARDINAL HEALTH, INC.
      • FIGURE 188     SWOT: CDH INVESTMENTS
      • FIGURE 189     SWOT: CURIUM PHARMA
      • FIGURE 190     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 191     SWOT: GE HEALTHCARE
      • FIGURE 192     SWOT: JUBILANT LIFESCIENCES
      • FIGURE 193     SWOT: LANTHEUS MEDICAL IMAGING INC.
      • FIGURE 194     SWOT: NOVARTIS INTERNATIONAL AG

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     13C MOLECULAR
      • 2     ACTINIUM PHARMACEUTICALS, INC
      • 3     ADVANCED NUCLEAR MEDICINE INGREDIENTS
      • 4     ALPHA TAU MEDICAL
      • 5     AMERICAN ELEMENTS
      • 6     AMERICAN RADIOLABELED CHEMICALS, INC.
      • 7     ARRONAX CYCLOTRON
      • 8     AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANIZATION (ANSTO)
      • 9     BAYER GROUP
      • 10     BEIJING ZHIBO BIOMEDICAL TECHNOLOGY CO. LTD
      • 11     BEST MEDICAL INTERNATIONAL, INC
      • 12     BOARD OF RADIATION & ISOTOPE TECHNOLOGY
      • 13     BOSTON SCIENTIFIC CORPORATION (BTG INTERNATIONAL LTD)
      • 14     BRACCO IMAGING S.P.A ( BLUE EARTH DIAGNOSIS)
      • 15     BUCHEM B.V.
      • 16     BV CYCLOTRON VU
      • 17     BWX TECHNOLOGIES (SOTERA HEALTH LLC (NORDION INC))
      • 18     CAMBRIDGE ISOTOPE LABORATORIES, INC. (ABX GMBH)
      • 19     CARDINAL HEALTH
      • 20     CARECAMP, INC
      • 21     CDH INVESTMENTS (SIRTEX MEDICAL LTD.)
      • 22     CELLECTAR BIOSCIENCES
      • 23     CENTER OF MOLECULAR RESEARCH (CMR)
      • 24     CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
      • 25     CLARITY’S PHARMACEUTICALS
      • 26     CURIUM PHARMA
      • 27     CYCLOPHARM LIMITED
      • 28     CYCLOTEK
      • 29     DIAMED
      • 30     DUCHEMBIO, INC
      • 31     ECKERT & ZIEGLER STRAHLEN
      • 32     ECZACIBAŞI-MONROL NUCLEAR PRODUCTS
      • 33     ELI LILLY & CO (AVID RADIOPHARMACEUTICALS)
      • 34     ENVIRO
      • 35     EURISOTOP
      • 36     FUJIFILM HOLDINGS CORPORATION
      • 37     FUTURECHEM CO., LTD
      • 38     GE COMPANY
      • 39     GT MEDICAL TECHNOLOGIES INC
      • 40     HILA PHARMA LTD
      • 41     HUAYI TECHNOLOGY CO., LTD (HUAYI ISOTOPES CO)
      • 42     INSTITUT RADIOFARMACIA APLICADA DE BARCELONA (IARB)
      • 43     INSTITUTE OF ISOTOPES
      • 44     INTERNATIONAL ISOTOPES INC.
      • 45     IRE ELIT
      • 46     ISOAID LLC
      • 47     ISO-ANALYTICAL LTD.
      • 48     ISOFLEX ISOTOPE
      • 49     ISOLOGIC
      • 50     ISORAD LTD
      • 51     ISORAY INC.,
      • 52     ISOSCIENCE, LLC
      • 53     ISO-TEX DIAGNOSTICS, INC.
      • 54     ISOTOPIA MOLECULAR IMAGING LTD.
      • 55     ITHEMBA LABS
      • 56     ITM ISOTOPEN TECHNOLOGIEN MÜNCHEN AG
      • 57     JSC ISOTOPE
      • 58     JUBILANT LIFESCIENCES
      • 59     KOREA ATOMIC ENERGY RESEARCH INSTITUTE
      • 60     LANTHEUS MEDICAL IMAGING
      • 61     LIFE MOLECULAR IMAGING
      • 62     LINDE GROUP
      • 63     LOS ALAMOS NATIONAL LABORATORY (LANL)
      • 64     MEDICAL ISOTOPES, INC
      • 65     MERCK KGAA (SIGMA ALDRICH-ISOTEC INC)
      • 66     MITSUBISHI CHEMICAL HOLDINGS (TAYYO NIPPON SANSO CORPORATION)
      • 67     MOLTEK
      • 68     NAVIDEA BIOPHARMACEUTICAL INC.
      • 69     NIHON-MEDI PHYSICS CO., LTD.
      • 70     NOVARTIS INTERNATIONAL AG (AAA)
      • 71     NUCLEAR RESEARCH AND CONSULTANCY GROUP (NRG)
      • 72     NUKEM ISOTOPES, GMBH
      • 73     OMICRON BIOCHEMICALS INC
      • 74     ORANO MED (AREVA MED)
      • 75     OTSUKA PHARMACEUTICAL (CAMBRIDGE ISOTOPE LABORATORIES, INC.)
      • 76     PARS ISOTOPE
      • 77     PERKINELMER INC.
      • 78     PERMA-FIX ENVIRONMENTAL SERVICES, INC. (PERMA FIX MEDICAL SA)
      • 79     PET PHARM BIOTECH CO., LTD
      • 80     POLATOM
      • 81     POSITRON PHARMA S.A.
      • 82     QMX LABORATORIES
      • 83     RADIOPREPARAT
      • 84     ROSATOM (JSC ISOTOPE)
      • 85     ROTOP PHARMAKA GMBH
      • 86     SAMYOUNG UNITECH CO., LTD
      • 87     SAYCARE THERAPEUTICS PVT, LTD.
      • 88     SHANGHAI GMS PHARMA
      • 89     SHANGHAI RESEARCH INSTITUTE OF CHEMICAL INDUSTRY
      • 90     SIEMENS AG
      • 91     SOLCOM LIMITED
      • 92     SOUTH AFRICAN NUCLEAR ENERGY CORPORATION (NTP)
      • 93     SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 94     SWAN ISOTOPEN AG
      • 95     TELIX PHARMACEUTICALS LIMITED
      • 96     TERUMO CORPORATION
      • 97     TEVA PHARMACEUTICAL INDUSTRIES LTD (AUSPEX PHARMACEUTICALS)
      • 98     THERAGENICS CORPORATION
      • 99     THERAGNOSTICS LTD
      • 100     TIANJIN SEEDS BIOLOGICAL PHARMACY CO. LTD
      • 101     TRACE SCIENCES INTERNATIONAL
      • 102     URENCO STABLE ISOTOPES
      • 103     VON GAHLEN NEDERLAND B.V.
      • 104     YANTAI DONGCHENG BIOCHEMICALS CO. LTD.
      • 105     ZAG ZYKLOTRON AG
      • 106     ZIONEXA SAS